Institut für Medizinische Statistik - UMG

Prof. Dr. Tim Friede


Institutsdirektor
Telefon:
0551-39-4991
Telefax:
0551-39-4995
E-Mail:
Tim.Friede@med.uni-goettingen.de
Ort:
Humboldtallee 32, EG 124
ORCID iD:
 orcid.org/0000-0001-5347-7441

Kurzbiographie

Seit Januar 2010 ist Tim Friede Professor für Biostatistik an der Universitätsmedizin Göttingen, wo er das Institut für Medizinische Statistik leitet. Nach seinem Diplom in Mathematik an der Universität Karlsruhe (TH) wurde er an der Medizinischen Fakultät der Universität Heidelberg zum Dr.sc.hum promoviert. Im Januar 2001 ging er nach Lancaster ans Department of Mathematics and Statistics zunächst als NHS Training Fellow in Medical Statistics und später als Lecturer in Biostatistics. Von 2004 an arbeitete er bei der Novartis Pharma AG in Basel, bevor er im Herbst 2006 an die Warwick Medical School als Associate Professor of Medical Statistics ging. In 2014 wurde ihm das Zertifikat „Biometrie in der Medizin“ der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie (GMDS) und der Deutschen Region der Internationalen Biometrischen Gesellschaft (IBS-DR) zuerkannt, das ihn als erfahrenen Studienstatistiker ausweist.

Seit 2011 ist Tim Friede auch geschäftsführender Leiter des Zentrums Informatik, Statistik und Epidemiologie, zu dem die Institute für Medizinische Informatik, für Medizinische Statistik, für Genetische Epidemiologie und für Bioinformatik gehören. Zudem ist er seit 2015 Mitglied im Sino-German Institute for Social Computing (SGISC), das sich mit interdisziplinärer Forschung in den Feldern Soziale Netze und BIG DATA beschäftigt. Das SGISC wurde gemeinsam von den Universitäten Göttingen und Nanjing, China gegründet.

Seit 2018 ist Tim Friede Präsident der Deutschen Arbeitsgemeinschaft Statistik (DAGStat). Von 2015 - 2018 war er Präsident der Deutschen Region der Internationalen Biometrischen Gesellschaft (IBS-DR). Zuvor war er Vize-Präsident und hat der Deutschen Region sowie der internationalen Muttergesellschaft in vielfältigen Funktionen gedient (Mitglied des internationalen Councils von 2008 – 2013, Mitglied im Editorial Advisory Committee 2008-2015, Mitglied des Beirates der Deutschen Region von 2005-2009).

Tim Friede ist Section Editor bei PLoS ONE sowie Associate Editor beim Biometrical Journal. Bis 2016 war er außerdem Associate Editor bei BMC Medical Research Methodology. Von 2009 – 2011 war Tim Friede Editor-in-Chief des Biometrical Journals zusammen mit Prof. Dr. Leonhard Held (Zürich) und von 2003-2011 Mitglied des Editorial Boards des Drug Information Journal.

Er ist Principal Investigator im Deutschen Zentrum für Herz-Kreislauf-Forschung (DZHK) und Studienstatistiker einer Vielzahl von klinischer Studien. Eine Übersicht der laufenden Forschungsprojekte findet sich unter Forschung.

Seine methodischen Forschungsinteressen liegen in der klinischen Biostatistik mit Schwerpunkten zu Designs für klinische Studien (insbesondere flexible adaptive Designs), zur generalisierten Evidenzsynthese (inkl. systematische Reviews und Meta-Analysen) und Anwendungen in seltenen Erkrankungen.

Tim Friede wurde von der GMDS 1999 mit dem Förderpreis für Studierende für seine Diplomarbeit „Adaptive Fallzahlplanung in klinischen Studien in der t-Test-Situation“ ausgezeichnet. Wenig später erhielt er dann 2001 den Nachwuchsförderpreis der Deutschen Region der Internationalen Biometrischen Gesellschaft (IBS-DR) für seine Dissertation zu internen Pilotstudien. In 2012 wurde ihm der Paul-Martini-Preis zur Förderung der Entwicklung wissenschaftlicher Methoden zur Beurteilung klinisch-pharmakologischer und therapeutischer Maßnahmen der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie (GMDS) gemeinsam mit Dr. Heinz Schmidli (Novartis Pharma AG, Basel, Schweiz) verliehen.


Ausgewählte Publikationen

Preprints
  1. Ursino M, Röver C, Zohar S, Friede T (2019) Random-effects meta-analysis of phase I dose-finding studies using stochastic process priors. [Preprint]
  2. Stegherr R, Beyersmann J, Jehl V, Rufibach K, Leverkus F, Schmoor C, Friede T on behalf of the SAVVY project group (2019) Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): Rationale and statistical concept of a meta-analytic study. [Preprint]
  3. Mütze T, Salem S, Benda N, Schmidli H, Friede T (2019) Blinded continuous information monitoring of recurrent event endpoints with time trends in clinical trials. [Preprint]
  4. Friede T, Stallard N, Parsons N (2019) Seamless phase II/III clinical trials using early outcomes for treatment or subgroup selection: Methods and aspects of their implementation. [Preprint]
  5. Günhan BK, Weber S, Seroutou A, Friede T (2018) Phase I dose-escalation trials with more than one dosing regimen. [Preprint]

In press
  1. Zapf A, Stark M, Gerke O, Ehret C, Benda N, Bossuyt P, Deeks J, Reitsma J, Alonzo T, Friede T (2019) Adaptive trial designs in diagnostic accuracy research. Statistics in Medicine (in press).
  2. Junttila MJ, Pelli A, Kenttä TV, Friede T, Willems R, Bergau L, Malik M, Vandenberk B, Vos MA, Schmidt G, Merkely B, Lubinski A, Svetlosak M, Braunschweig F, Harden M, Zabel M, Huikuri HV, Sticherling C (2019) Appropriate Shocks and Mortality in Patients With Versus Without Diabetes With Prophylactic Implantable Cardioverter Defibrillators Diabetes Care (in press, available online)
  3. Zabel M, Schlögl S, Lubinski A, Svendsen J, Bauer A, Arbelo E, Brusich S, Conen D, Cygankiewicz I, Dommasch M, Flevari P, Galuszka J, Katsimardos A, Hansen J, Hasenfuss G, Hatala R, Huikuri H, Kentta T, Kuczejko T, Haarmann H, Harden M, Iovev S, Kääb S, Kaliska G, Kasprzak JD, Qavoq D, Luthje L, Malik M, Novotny T, Pavlovic N, Perge P, Röver C, Schmidt G, Shalganov T, Sritharan R, Svetlosak M, Sallo Z, Szavits‑Nossan J, Traykov V, Vandenberk B, Velchev V, Vos M, Willich SN, Friede T, Willems R, Merkely B, Sticherling C (2019) Present criteria for prophylactic ICD implantation: Insights from the EU-CERT-ICD (Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in EUrope) project. Journal of Electrocardiology. (in press, available online)
  4. Günhan BK, Röver C, Friede T, (2019) Meta-analysis of few studies involving rare events. Research Synthesis Methods.(in press, available online)
  5. Fokas E, Allgäuer M, Polat B MD3, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL, Schmiegel W, Jacobasch L, Weitz J, Folprecht G, Schlenska-Lange A, Flentje M, Germer CT, Grützmann R, Schwarzbach M, Paolucci V, Bechstein W, Friede T, Ghadimi M, Hofheinz RD, Rödel C, on behalf of the German Rectal Cancer Study Group (2019) Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. Journal of Clinical Oncology. (in press, available online)

  6. 2019
  7. Oellerich M, Shipkova M, Asendorf T, Walson PD, Schauerte V, Mettenmeyer N, Kabakchiev M, Hasche G, Gröne HJ, Friede T, Wieland E, Schwenger V, Schütz E, Beck J (2019) Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation - Results from a prospective observational study. American Journal of Transplantation. American Journal of Transplantation 19: 3087–3099. [Open access]
  8. Bauer A, Klemm M, Rizas KD, Hamm W, von Stülpnagel L, Lubinsky A, Flevari P, Harden M, Friede T, Kääb S, Merkely B, Sticherling C, Willems R, Huikuri H, Malik M, Schmidt G, Zabel M (2019) Periodic repolarization dynamics predicts the mortality benefit in patients undergoing prophylactic implantation of a defibrillator: a prospective controlled multicentre observational study. The Lancet 394:1344-1351. [Abstract]
  9. Bobenko A, Schoenrath F, Knierim JH, Friede T, Verheyen N, Mehra MR, Haykowsky M, Herrmann-Lingen C, Duvinage A, Pieske-Kraigher E, Halle M, Falk V, Pieske B, Edelmann F (2019) Exercise training in patients with a left ventricular assist device (Ex-VAD): rationale and design of a multicentre, prospective, assessor-blinded, randomized, controlled trial. European Journal of Heart Failure, 21: 1152-1159. [Open access]
  10. Röver C, Friede, T (2019) Dynamically borrowing strength from another study through shrinkage estimation. Statistical Methods in Medical Research. [Open access]
  11. Rommer PS, Eichstädt K, Ellenberger D, Flachenecker P, Friede T, Haas J, Kleinschnitz C, Pöhlau D, Rienhoff O, Stahmann A, Zettl UK (2019) Symptomatology and symptomatic treatment in multiple sclerosis: results from a nationwide MS registry. Multiple Sclerosis Journal. [Abstract]
  12. Huber C, Benda N, Friede T (2019) A comparison of subgroup identification methods in clinical drug development: Simulation study and regulatory considerations. Pharmaceutical Statistics 18:600–626 [Open access]
  13. Nicholas RS, Han E, Raffel J, Chataway J, Friede T (2019) Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: a systematic review and meta-analysis of 43 randomized placebo-controlled trials. Multiple Sclerosis Journal 25: 1462–1471.
  14. [Abstract]
  15. Posch M, Bretz F, Friede T, Heinze G (2019) Quantitative approaches underpinning decision making. Biometrical Journal 61: 1103. [Open access]
  16. Andreas S, Röver C, Heinz J, Straube S, Watz H, Friede T (2019) Decline of COPD exacerbations in clinical trials over two decades - a systematic review and meta-regression. Respiratory Research 20:186. [Open Access]
  17. Mütze T, Glimm E, Schmidli H, Friede T (2019) Group sequential designs with robust semiparametric recurrent event models. Statistical Methods in Medical Research 28: 2385–2403. [Abstract]
  18. Mütze T, Glimm E, Schmidli H, Friede T (2019). Group sequential designs for negative binomial outcomes. Statistical Methods in Medical Research 28: 2326–2347. [Abstract]
  19. Placzek M, Friede T (2019) A conditional error function approach for adaptive enrichment designs with continuous endpoints. Statistics in Medicine 38: 3105-3122. [Abstract]
  20. Zabel M, Sticherling C, Willems R, Lubinski A, Bauer A, Bergau L, Braunschweig F, Brugada J, Brusich S, Conen D, Cygankiewicz I, Flevari P, Taborsky M, Hansen J, Hasenfuß G, Hatala R, Huikuri HV, lovev S, Kääb S, Kaliska G, Jaroslaw D. Kasprzak JD, Lüthje L, Malik M, Novotný T, Pavlovic N, Schmidt G, Shalganov T, Sritharan R, Schlögl S, Szavits-Nossan J, Traykov V, Tuinenburg A, Velchev V, Vos MA, Willich SN, Friede T, Svendsen JH, Merkely B for the EU-CERT-ICD Study lnvestigators (2018) Rationale and Design of the EU-CERT-ICD Prospective Study: Comparative Effectiveness of Prophylactic ICD Implantation. ESC Heart Failure 6: 182-193 [Open Access]
  21. Graf AC, Wassmer G, Friede T, Gera RG, Posch M (2019) Robustness of testing procedures for confirmatory subpopulation analyses based on a continuous biomarker. Statistical Methods in Medical Research 28: 1879-1892. [Open access]
  22. Friede T, Pohlmann H, Schmidli H (2019) Blinded sample size reestimation in event-driven clinical trials: Methods and an application in multiple sclerosis. Pharmaceutical Statistics 18: 351–365. [Abstract]
  23. Konietschke F, Friede T, Pauly M (2019) Semi-parametric analysis of over-dispersed count and metric data with varying follow-up times: Asymptotic theory and small sample approximations. Biometrical Journal 61: 616–629. [Open Access]
  24. Asendorf T, Henderson R, Schmidli H, Friede T (2019) Sample size reestimation for clinical trials with longitudinal negative binomial counts including time trends. Statistics in Medicine 38: 1503–1528. [Abstract]
  25. Lingor P, Weber M, Camu W, Friede T, Hilgers R, Leha A, Christoph Neuwirth C, Günther R, Benatar M, Kuzma-Kozakiewicz M, Bidner H, Blankenstein C, Frontini R, Ludolph A, Koch JC and the ROCK-ALS Investigators (2019) ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. Frontiers in Neurology 10: 293. [Open Access]
  26. Unkel S, Amiri M, Benda N, Beyersmann J, Knoerzer D, Kupas K, Langer F, Leverkus F, Loos A, Ose C, Proctor T, Schmoor C, Schwenke C, Skipka G, Unnebrink K, Voss F, Friede T (2019) On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies. Pharmaceutical Statistics 18:166–183 [Open Access]
  27. Friede T, Häring DA, Schmidli H (2019) Blinded continuous monitoring in clinical trials with recurrent event endpoints. Pharmaceutical Statistics 18: 54–64. [Open Access].
  28. Mollenhauer B, Zimmermann J, Sixel-Döring F, Focke NK, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Friede T, Trenkwalder C on behalf of the DeNoPa Study Group (2019) Baseline predictors for progression in early Parkinson’s disease after 4-year follow-up from the DeNoPa cohort. Movement Disorders 34: 67-77. [Abstract]
  29. Röver C, Wandel S, Friede T (2019) Model averaging for robust extrapolation in evidence synthesis. Statistics in Medicine 38:674–694. [Abstract]
  30. Ursino M, Yuan Y, Alberti C, Comets E, Favrais G, Friede T, Lentz F, Stallard N, Zohar S (2019) A dose-finding design for seizure reduction in neonates. Journal of the Royal Statistical Society Series C 68: 427–444. [Open Access]
  31. Seide SE, Röver C, Friede T (2019) Likelihood-based meta-analysis with few studies: Empirical and simulation studies. BMC Medical Research Methodology 19: 16. [Open Access]
  32. Asendorf T, Henderson R, Schmidli H, Friede T (2019) Modelling and sample size reestimation for longitudinal count data with incomplete follow up. Statistical Methods in Medical Research 28: 117–133. [Abstract]

  33. 2018
  34. Scholz KH, Friede T, Meyer T, Jacobshagen C, Lengenfelder B, Jung J, Fleischmann C, Moehlis H, Olbrich HG, Ott R, Elsässer A, Schröder S, Thilo C, Raut W, Franke A, Maier LS, Maier SKG (2018) Prognostic significance of emergency department bypass in stable and unstable patients with ST-segment elevation myocardial infarction. European Heart Journal: Acute Cardiovascular Care. [Open access]
  35. Gibbons C, Pagnini F, Friede T, Young CA (2018) Treatment of fatigue in amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2018, Issue 1: CD011005. [Full text]
  36. Friede T (2018) Klinische Studien und Meta-Analysen. In: Andreas S, Watz H (eds.) COPD: Aktuelles und praxisrelevantes Wissen zur chronisch obstruktiven Lungenerkrankung (Chapter 1.2; 10 pages). Walter de Gruyter, Berlin / Boston. [Abstract]
  37. Harden M, Friede T (2018) Sample size calculation in multi-centre clinical trials. BMC Medical Research Methodology 18:156 [Open Access]
  38. Röver C, Friede T (2018) Contribution to the discussion of "When should meta-analysis avoid making hidden normality assumptions?": A Bayesian perspective. Biometrical Journal 60: 1068-1070. [Abstract]
  39. Bergau L, Willems R, Dunnink A, Tuinenburg AE, Flevari P, Vos MA, Vandenberk B, Wijers SC, Katsaras D, Lüthje L, Seegers J, Sossalla ST, Fischer TH, Röver C, Lehnart SE, Hasenfuß G, Friede T, Zabel M (2018) Differential multivariable risk prediction of appropriate shock versuse competing mortality – A prospective cohort study to estimate benefits from ICD therapy. International Journal of Cardiology 272: 102–107. [Open Access]
  40. Maiolo G, Collino F, Vasques F, Rapetti F, Tonetti T, Romitti F, Cressoni M, Chiumello D, Mörer O, Herrmann P, Friede T, Quintel M, Gattinoni L (2018) Reclassifying Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine 197: 1586-1595. [Abstract]
  41. Pöttgen J, Moss-Morris R, Wendebourg JM, Feddersen L, Lau S, Köpke S, Meyer B, Friede T, Penner IK, Heesen C, Gold S (2018) Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry 89: 970–976. [Abstract]
  42. Stürner KH, Stellmann JP, Dörr J, Paul F, Friede T, Schammler S, Reinhardt S, Siemonsen S, Weisspflog G, Faizy T, Werz O, Fleischer S, Vaaß L, Hermann F, Pless O, Martin R, Heesen C (2018) A standardized frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis in a phase II a trial (The SABA Trial). Journal of Neurology, Neurosurgery and Psychiatry 89: 330–338. [Full text]
  43. Friede T, Posch M, Zohar S, Alberti C, Benda N, Comets E, Day S, Dmitrienko A, Graf A, Gunhan B, Hee SW, Lentz F, Madan J, Miller F, Ondra T, Pearce M, Röver C, Toumazi A, Unkel S, Ursino M, Wassmer G, Stallard N (2018) Recent advances in methodology for clinical trials in small populations: the InSPiRe project. Orphanet Journal of Rare Diseases 13: 186. [Open Access]
  44. Placzek M, Friede T (2018) Clinical trials with nested subgroups: Analysis, sample Size determination and internal pilot studies. Statistical Methods in Medical Research 27: 3286–3303. [Abstract]
  45. Bender R, Friede T, Koch A, Kuß O, Schlattmann P, Schwarzer G, Skipka G (2018) Methods for evidence synthesis in the case of very few studies. Research Synthesis Methods 9: 382–392. [Open Access]
  46. Stork L, Ellenberger D, Beißbarth T, Friede T, Lucchinetti CF, Brück W, Metz I (2018) Differences in the reponses to apheresis therapy of patients with 3 histopathologically classified immunopathological patterns of multiple sclerosis. JAMA Neurology 75: 428-435. [Full text]
  47. Afshar K, Fleischmann N, Schmiemann G, Bleidorn J, Hummers-Pradier E, Friede T, Wegscheider K, Moore M, Gágyor I (2018) Reducing antibiotic use for uncomplicated urinary tract infection in general practice by treatment with Uva ursi (REGATTA) - a double-blind, randomized, controlled comparative effectiveness trial. BMC Complementary and Alternative Medicine 18: 203. [Open Access]
  48. Sticherling C, Arendacka B, Hastrup Svendsen J, Wijers S, Friede T, Stockinger J, Dommasch M, Merkely B, Willems R, Lubinski A, Scharfe M, Braunschweig F, Svetlosak M, Zürn CS, Huikuri H, Flevari P, Lund-Andersen C, Schaer BA, Tuinenburg AE, Bergau L, Schmidt G, Szeplaki G, Vanderberk B, Kowalczyk E, Eick C, Juntilla J, Conen D, Zabel M for the EU-CERT-ICD investigators (2018) Sex Differences in Outcomes of Primary Prevention ICD Therapy: Combined Registry Data from Eleven European countries. Europace 20: 963–970. [Open Access]
  49. Scholz KH, Maier SKG, Maier LS, Lengenfelder B, Jacobshagen C, Jung J, Fleischmann C, Werner GS, Olbrich HG, Ott R, Mudra H, Seidl K, Schulze C, Weiss C, Zrenner B, Friede T, Meyer T (2018) Effects of treatment delay on mortality in patients with ST-segment elevation myocardial infarction and hemodynamic instability. Results from the German prospective, multicenter FITT-STEMI trial. European Heart Journal 39: 1065–1074. [Open Access]
  50. Mütze T, Schmidli H, Friede T (2018) Sample size re-estimation incorporating prior information on a nuisance parameter. Pharmaceutical Statistics 17: 126-143. [Abstract]
  51. Toumazi A., Comets E, Alberti C, Friede T, Lentz F, Stallard N, Zohar S, Ursino M (2018) dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials. Computer Methods and Programs in Biomedicine 157: 163–177. [Abstract]
  52. Günhan BK, Friede T, Held L (2018) A design-by-treatment interaction model for network meta-analysis with integrated nested Laplace approximations. Research Synthesis Methods 9:179–194. [Open Access]
  53. Hellenkamp K, Unsöld B, Mushemi-Blake S, Shah AM, Friede T, Hasenfuß G, Seidler T (2018) Echocardiographic estimation of mean pulmonary artery pressure – a comparison of different approaches to assign the likelihood of pulmonary hypertension. Journal of the American Society of Echocardiography 31: 89-98. [Abstract]
  54. Friede T (2018) Clinical trial design: statistical issues. In: Camm AJ, Lüscher TF, Maurer G, Serruys PW (eds) . ESC CardioMed (3rd edition).

  55. 2017
  56. Makedonski P, Friede T, Grabowski J, Koschack J, Himmel W (2017) Information flows in patient-oriented online media and scientific research. In: Fu X, Luo JD, Boos M. Social Network Analysis - Interdisciplinary Approaches and Case Studies. CRC Press.
  57. Nicholas RS, Nandoskar A, Hutchinson M, Friede T (2017) Trials of novel therapies specifically for progressive MS. In: Wilkins A (Ed.) Progressive Multiple Sclerosis. Springer.
  58. Balcarek P, Rehn S, Howells NR, Eldridge JD, Kita K, Dejour D, Nelitz M, Harden M, Friede T (2016) Results of Trochleoplasty versus Medial Patellofemoral Ligament Reconstruction in Patellar Instability caused by severe Trochlear Dysplasia - A Systematic Review and Meta-Analysis. Knee Surgery, Sports Traumatology, Arthroscopy 25: 3869-3877. [Abstract]
  59. Gross O, Kashtan CE, Rheault M, Flinter F, Savige J, Miner JH, Torra R, Ars E, Deltas C, Savva I, Perin L, Renieri A, Ariani F, Mari F, Baigent C, Judge P, Knebelman B, Heidet L, Lagas S, Blatt D, Ding J, Zhang Y, Gale1 DP, Prunotto M, Xue Y, Schachter AD, Morton LCG, Blem J, Huang M, Liu S, Vallee S, Renault D, Schifter J, Skelding J, Gear S, Friede T, Turner AN, Lennon R (2017) Advances and Unmet Needs in Genetics, Basic and Clinical Science in Alport syndrome: Report from the 2015 International Workshop on Alport Syndrome. Nephrology Dialysis Transplantation 32: 916-924. [Open Access]
  60. Gold SM, Enck P, Hasselmann H, Friede T, Hegerl U, Mohr DC, Otto C (2017) Control conditions for randomized trials of behavioral interventions in psychiatry: A decision framework. Lancet Psychiatry 4: 725–732. [Abstract]
  61. Wandel S, Neuenschwander B, Röver C, Friede T (2017) Using phase II data for the analysis of phase III studies: an application in rare diseases. Clinical Trials 14: 277-285. [Abstract]
  62. Nadoskar A, Raffel J, Scalfari AS, Friede T, Nicholas RS (2017) Pharmacological approaches to the management of secondary progressive multiple sclerosis. Drugs 77: 885-910. [Abstract] 
  63. Filippatos GS, de Graeff P, Bax JJ, Borg JJ, Cleland JGF, Dargie HJ, Flather M, Ford I, Friede T, Greenberg B, Henon-Goburdhun C, Holcomb R, Horst B, Lekakis J, Mueller-Velten G, Papavassiliou AG, Prasad K, Rosano GMC, Severin T, Sherman W, Gattis Stough W, Swedberg K, Tavazzi L, Tousoulis D, Vardas P, Ruschitzka F, Anker SD (2017) Independent Academic Data Monitoring Committees for Clinical Trials in Cardiovascular and Cardiometabolic Diseases. European Heart Failure Journal 19: 449–456. [Abstract]
  64. Bergau L, Tichelbäcker T, Kessel B, Lüthje L, Fischer TH, Friede T, Zabel M (2017) Predictors of mortality and ICD shock therapy in primary prophylactic ICD patients - A systematic review and meta-analysis. PLOS ONE 12: e0186387. [Open Access].
  65. Mütze T, Friede T (2017). Blinded sample size re-estimation in three-arm trials with 'gold standard' design. Statistics in Medicine 36: 3636–3653. [Abstract]
  66. Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, Fischer K, Hellwig, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Young KL, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl U, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Kleiter I on behalf of NEMOS (Neuromyelitis Optica Study Group) (2017) Immunotherapies in neuromyelitis optica spectrum disorder: Efficacy and predictors of response. Journal of Neurology, Neurosurgery and Psychiatry 88: 639-647. [Open access]
  67. Raffel J, Wallace A, Gveric D, Reynolds R, Friede T, Nicholas R (2017) Patient-reported outcomes and survival in multiple sclerosis: a 10-year retrospective cohort study using the MSIS-29. PLOS Medicine 14: e1002346 [Open Access]
  68. Friede T, Röver C, Wandel S, Neuenschwander B (2017) Meta-analysis of two studies in the presence of heterogeneity with applications in rare diseases. Biometrical Journal 59: 658–671. [Abstract]
  69. Schmidli H, Neuenschwander B, Friede T (2017) Meta-analytic-predictive use of historical variance data for the design and analysis of clinical trials. Computational Statistics & Data Analysis 113: 100-110. [Abstract]
  70. Messroghli DR, Pickardt T, Fischer M, Opgen-Rhein B, Papakostas K, Böcker D, Jakob A, Khalil M, Mueller GC, Schmidt F, Kaestner M, Udink ten Cate FEA, Wagner R, Ruf B, Kiski D, Wiegand G, Franziska Degener F, Bauer UMM, Friede T, Schubert S on behalf of the MYKKE consortium (2017) Towards evidence-based diagnosis and therapy of myocarditis in children and adolescents: Rationale, design, and first baseline data of MYKKE, a multi-centre registry and study platform. The American Heart Journal 187: 133-144. [Abstract]
  71. Seegers J, Hnatkova K, Friede T, Malik M, Zabel M (2017) T-wave loop area from a pre-implant 12-lead ECG is associated with appropriate ICD shocks. PLOS ONE 12: e0173868. [Open Access]
  72. Varges D, Manthey H, Heinemann U, Ponto C, Schmitz M, Krasnianski A, Breithaupt M, Fincke F, Kramer K, Friede T, Zerr I (2017) Doxycycline in early CJD – double-blinded randomized phase II and observational study. Journal of Neurology, Neurosurgery & Psychiatry 88: 119–125. [Open Access]
  73. Ursino M, Zohar S, Lentz F, Alberti C, Friede T, Stallard N, Comtes E (2017) Dose-finding methods using pharmacokinetics in small populations. Biometrical Journal 59: 804-825. [Open Access].
  74. Kunz CU, Stallard N, Parsons N, Todd S, Friede T (2017) Blinded versus unblinded estimation of a correlation coefficient to inform interim design adaptations. Biometrical Journal 2: 344–357. [Open Access].
  75. Wegscheider K, Friede T (2017) Do we consent to rules of consent and confidentiality? Biometrical Journal 2: 235–239.
  76. Friede T, Röver C, Wandel S, Neuenschwander B (2017) Meta-analysis of few small studies in orphan diseases. Research Synthesis Methods 8: 79–91. [Open Access].
  77. Röver C, Friede T (2017) Discrete approximation of a mixture distribution via restricted divergence. Journal of Computational and Graphical Statistics 26:217-222. [Abstract] .
  78. Mütze T, Konietschke F, Munk A, Friede T (2017) A studentized permutation test for three-arm trials in the ‘gold standard’ design. Statistics in Medicine 36: 883–898. [Abstract]

  79. 2016
  80. Mollenhauer B, Zimmermann J, Sixel-Döring F, Focke NK, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Trautmann E, Zetterberg H, Taylor P, Friede T, Trenkwalder C & the DeNoPa Study Group (2016) Monitoring of thirty marker candidates in early Parkinson’s disease as progression markers. Neurology 87: 168-77.
  81. Metz I, Beißbarth T, Ellenberger D, Pache F, Stork L, Ringelstein M, Aktas O, Jarius S, Wildemann BT, Dihazi H, Friede T, Brück W, Ruprecht K, Paul F (2016) Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis.Neurology: Neuroimmunology & Neuroinflammation 3: e204. [Open Access]
  82. Jackson N, Atar D, Maria Borentain M, Breithardt G, van Eickels M, Endres M, Fraass U, Friede T, Hannachi H, Janmohamed S, Kreuzer J, Landray M, Lautsch D, Le Floch C, Moll P, Naci1 H, Samani1 NJ, Svensson A, Thorstensen C, Tijssen J, Vandzhura V, Zalewski A, Kirchhof P (2016) Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. European Heart Journal 37: 747-754.
  83. Seegers J, Conen D, Jung K, Bergau L, Dorenkamp M, Munoz Exposito P, Lüthje L, Sohns C, Sossalla ST, Fischer TH, Hasenfuss G, Friede T, Zabel M (2016) Sex difference in appropriate shocks but not mortality during long-term follow-up in patients with implantable cardioverter-defibrillators. EP Europace 18: 1194–1202.
  84. Straube S, Harden M, Schröder H, Arendacka B, Fan X, Moore A, Friede T (2016) Back schools for the treatment of chronic low back pain: possibility of benefit but no convincing evidence after 47 years of research – systematic review and meta-analysis. Pain 157: 2160–2172. [Open Access]
  85. Olthoff A, Carstens PO, Zhang S, von Fintel E, Friede T, Lotz J, Frahm J, Schmidt J (2016) Evaluation of dysphagia by novel real-time magnetic resonance imaging. Neurology 87: 2132-2138.
  86. Patel S, Hee SW, Mistry D, Jordan J, Brown S, Dritsaki M, Ellard DR, Friede T, Lamb SE, Lord J, Madan J, Morris T, Stallard N, Colin Tysall, Adrian Willis, Underwood M and the Repository Group (2016) Identifying back pain subgroups: developing and applying approaches using individual patient data collected within clinical trials. Programme Grants for Applied Research 4 (10). [Open Access]
  87. Conen D, Arendacka B, Röver C, Bergau L, Munoz P, Wijers S, Sticherling C, Zabel M, Friede T (2016) Gender differences in appropriate shocks and mortality among patients with primary prophylactic implantable cardioverter-defibrillators: Systematic review and meta-analysis. PLoS ONE 11: e0162756. [Abstract]
  88. Ellenberger D, Friede T (2016) An unconditional test for change point detection in binary sequences with applications to clinical registries. Methods of Information in Medicine 55: 367–372. [Abstract]
  89. Nicotra A, Claus Newman C, Eremin O, Friede T, Malik O, Nicholas R (2016) Peripheral nerve dysfunction in middle-aged subjects born with thalidomide embryopathy. PLoS ONE 11: e0152902. [Open Access]
  90. Seegers J, Bergau L, Muñoz Expósito P, Bauer A, Fischer T, Lüthje L, Hasenfuß G, Friede T, Zabel M (2016) Prediction of appropriate shocks using 24-hour holter variables and T-wave alternans following first implantable cardioverter-defibrillator implantation in patients with ischemic and non-ischemic cardiomyopathy. American Journal of Cardiology 118: 86-94. [Open Access].
  91. Sudlow R, Branson J, Friede T, Morgan D, Whately-Smith C (2016) EFSPI/PSI Working Group on Data Sharing: Accessing and Working with Pharmaceutical Clinical Trial Patient Level Datasets – a Primer for Academic Researchers. BMC Medical Research Methodology 16: 73. [Open Access]
  92. Chataway J, Friede T (2016) The N-MOmentum trial: building momentum to advance trial methodology in a rare disease. Multiple Sclerosis Journal 22: 852–853.
  93. Sterz C, Ellenberger D, Meissner H, Friede T, Flachenecker P (2016) Employment-associated factors in multiple sclerosis – results of a cross sectional study in Germany. Edorium Journal of Disability and Rehabilitation 2: 24–33. [Open Access]
  94. Unkel S, Röver C, Stallard N, Benda N, Posch M, Zohar S, Friede T (2016) Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions. Orphanet Journal of Rare Diseases 11: 16. [Open access]
  95. Mütze T, Munk A, Friede T (2016) Design and analysis of three-arm trials with negative binomially distributed endpoints. Statistics in Medicine 35: 505–521.
  96. Ondra T, Dmitrienko A, Friede T, Graf A, Miller F, Stallard N, Posch M (2016) Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review. Journal of Biopharmaceutical Statistics 26: 99-119. [Open access]
  97. Röver C, Andreas S, Friede T (2016) Evidence synthesis for count distributions based on heterogeneous and incomplete aggregated data. Biometrical Journal 58: 170-185. [Abstract].

  98. 2015
  99. Helms HJ, Benda N, Friede T (2015) Point and interval estimators of the target dose in clinical dose-finding studies with active control. Journal of Biopharmaceutical Statistics 25: 939–957. [Open Access]
  100. Dugas M, Jöckel KH, Friede T, Gefeller O, Kieser M, Marschollek M, Ammenwerth E, R. Röhrig R, Knaup-Gregori P, Prokosch HU (2015) Memorandum “Open Metadata”: Open Access to documentation forms and item catalogs in healthcare. Methods of Information in Medicine 54: 376–378. [Abstract]
  101. Helms HJ, Benda N, Zinserling J, Kneib T, Friede T (2015) Spline-based procedures for dose-finding studies with active control. Statistics in Medicine 34: 232-248. [Open Access]
  102. Koschack J, Weibezahl L, Friede T, Himmel W, Makedonski P, Grabowski J (2015) Scientific versus experiential evidence: Discourse analysis of the CCSVI debate in a multiple sclerosis forum. Journal of Medical Internet Research 17: e159. [Open access]
  103. Kunz CU, Friede T, Parsons N, Todd S, Stallard N (2015) A comparison of methods for treatment selection in seamless phase II /III clinical trials incorporating information on short-term endpoints. Journal of Biopharmaceutical Statistics 25: 170-189. [Open Access]
  104. Rommer PS, Buckow K, Ellenberger D, Friede T, Pitschnau-Michel D, Fuge J, Stüve O, Zettl UK for the German Multiple Sclerosis (MS) Registry of the German National MS Society (DMSG) (2015) Patients’ characteristics influencing the longitudinal utilization of steroids in multiple sclerosis – an observational study. European Journal of Clinical Investigation 45: 587-593. [Abstract]
  105. Röver C, Knapp G, Friede T (2015) Hartung-Knapp-Sidik-Jonkman approach andits modification for random-effects meta-analysis with few studies. BMC Medical Research Methodology, 15: 99. [Open Access]
  106. Röver C, Nicholas R, Straube S, Friede T (2015) Changing EDSS progression in placebo cohorts in relapsing MS: A systematic review and meta-regression. PLoS ONE 10: e0137052. [Open Access]
  107. Schmidt C, Gerlach N, Peter C, Gherib K, Lange K, Friede T, Zerr I (2015) CSF Apolipoprotein E Concentration and Progression of Alzheimer's Disease. Journal of Alzheimer’s Disease 43: 1229-1236. [Abstract]
  108. Schmidt C, Gerlach N, Schmitz M, Thom T, Kramer K, Friede T, Zerr I (2015) Baseline CSF/serum-ratio of apolipoprotein E and rate of differential decline in Alzheimer’s disease. Journal of Alzheimer’s Disease 48: 189–196. [Abstract]
  109. Stallard N, Kunz CU, Todd S, Parsons N, Friede T (2015) Flexible selection of a single treatment incorporating short-term endpoint information in a phase II/III clinical trial. Statistics in Medicine 34: 3104-3115. [Open Access ]
  110. Stellmann JP, Stürner KH, Young KL, Siemonsen S, Friede T, Heesen C (2015) Regression to the mean and predictors of MRI disease activity in RRMS placebo cohorts - is there a place for baseline-to-treatment studies in MS? PLoS ONE 10: e0116559. [Open Access]
  111. Straube S, Werny B, Friede T (2015) A systematic review identifies shortcomings in the reporting of cross-over trials in chronic painful conditions. Journal of Clinical Epidemiology 68: 1496-1503. [Abstract]

  112. 2014
  113. Chenot JF, Hua TD, Abu Abed M, Schneider-Rudt H, Friede T, Schneider S, Vormfelde SV (2014) Safety relevant knowledge of orally anticoagulated patients: a baseline survey in primary care. BMC Family Health: 15: 104. [Open Access]
  114. Chenot JF, Weber P, Friede T (2014) Efficacy of Ambroxol lozenges for sore throat: a meta-analysis. BMC Family Practice 15: 45. [Open Access]
  115. Crins ND, Röver C, Goralczyk AD, Friede T (2014) Interleukin-2 Receptor Antagonists for Pediatric Liver Transplant Recipients: A Systematic Review and Meta-Analysis of Controlled Studies. Pediatric Transplantation 18: 839-850. [Abstract]
  116. Dugas M, Jöckel KH, Gefeller O, Knaup-Gregori P, Friede T, Ammenwerth E, Kieser M, Prokosch HU (2014) Freier Zugang zu Dokumentationsformularen und Merkmalskatalogen im Gesundheitswesen. Memorandum „Open Metadata“. GMS Med Inform Biom Epidemiol. 10: 1. [Open Access]
  117. Flachenecker P, Buckow K, Pugliatti M, Bašic Kes V, Battaglia MA, Boyko A, Ellenberger D, Eskic D, Ford D, Friede T, Fuge J, Glaser A, Hillert J, Holloway E, Ioannidou E, Kappos L for the EUReMS Consortium (2014) Multiple sclerosis registries in Europe – results of a systematic survey. Multiple Sclerosis Journal 20: 1523-1532. [Abstract]
  118. Golkowski D, Friede T, Kieser M (2014) Blinded sample size re-estimation in crossover bioequivalence trials. Pharmaceutical Statistics 13: 157–162. [Abstract]
  119. Huppke B, Ellenberger D, Rosewich H, Friede T, Gärtner J, Huppke P (2014) Clinical presentation of pediatric multiple sclerosis before puberty. European Journal of Neurology 2: 441-446. [Abstract]
  120. Kunz CU, Friede T, Parsons N, Todd S, Stallard N (2014) Data-driven treatment selection for seamless phase II/III trials incorporating early-outcome data. Pharmaceutical Statistics 13: 238–246. [Open Access]
  121. Patel S, Ngunjiri A, Hee SW, Yang Y, Brown S, Friede T, Griffiths F, Lord J, Sandhu H, Thistlethwaite J, Tysall C, Underwood M (2014) Primum non nocere: Shared informed decision making in low back pain – A pilot cluster randomised trial. BMC Musculoskeletal Disorders 15: 282. [Open Access]
  122. Patel S, Ngunjiri A, Sandhu H, Griffiths F, Thistlethwaite J, Brown S, Friede T, Lord J, Colin Tysall C, Woolvine M, Underwood M (2014) The design and development of a decision support package for low back pain. Arthritis Care & Research 66: 925-933. [Open Access]
  123. Schmidt C, Becker H, Peter C, Lange K, Friede T, Zerr I (2014) Plasma prion protein concentration and progression of Alzheimer's disease. Prion 8: 12-16. [Open access]
  124. Schmidt C, Wolff M, von Ahsen N, Lange K, Friede T, Zerr I (2014) CR1 is potentially associated with rate of decline in sporadic Alzheimer's disease. Journal of Clinical Neuroscience 21: 1705-1708. [Abstract]
  125. Stallard N, Homburg T, Parsons N, Friede T (2014) Adaptive designs for confirmatory clinical trials with subgroup selection. Journal of Biopharmaceutical Statistics 24: 168-187. [Abstract]
  126. Sudau F, Friede T, Grabowski J, Koschack J, Makedonski P, Himmel W (2014) Sources of Information and Behavioral Patterns in Health Online Forums: Observational Study. J Med Internet Res 16: e10. [Open Access]
  127. Vormfelde SV, Abed MA, Hua TD, Schneider S, Friede T, Chenot JF (2014) Schulung oral antikoagulierter Patienten zur Arzneimitteltherapiesicherheit - eine cluster-randomisierte Studie in Hausarztpraxen (Educating orally anticoagulated patients in drug safety – a cluster-randomized study in general practice). Deutsches Ärzteblatt 111: 607-614. [Open Access]
  128. Wolf I, Friede T, Hallier E, Straube S (2014) Work-related outcomes in randomised placebo-controlled pain trials: a systematic review and meta-analysis. Journal of Occupational Medicine and Toxicology 9: 25. [Open Access]

  129. 2013
  130. Friede T, Kieser M (2013) Blinded sample size re-estimation in superiority and non-inferiority trials: Bias versus variance in variance estimation. Pharmaceutical Statistics 12: 141–146. [Abstract]
  131. Kieser M, Friede T, Gondan M (2013) Assessment of statistical significance and clinical relevance. Statistics in Medicine 32: 1707–1719. [Abstract]
  132. Kombrink K, Munk A, Friede T (2013) Design and semiparametric analysis of non-inferiority trials with active and placebo control for censored time to event data. Statistics in Medicine 32: 3055-3066. [Abstract].
  133. Koziolek MJ, Mühlhausen J, Friede T, Ellenberger D, Sigler M, Gärtner J, Müller GA, Huppke P (2013) Therapeutic apheresis in pediatric patients with acute CNS inflammatory demyelinating disease. Blood Purification 36: 92–97. [Full text]
  134. Kruss S, Erpenbeck L, Amschler K, Mundinger TA, Böhm H, Helms HJ, Friede T, Andrews RK, Schön MP, Spatz JP (2013) Adhesion Maturation of neutrophils on nanoscopically presented platelet glycoprotein Ibα. ACS Nano 7: 9984-9996. [Abstract]
  135. Mollenhauer B, Trautmann E, Sixel-Döring F, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Focke NK, Kumar K, Lohmann K, Klein C, Schlossmacher M, Kohnen R, Friede T, Trenkwalder C (2013) Non-motor and diagnostic findings in de novo Parkinson’s disease subjects of the DeNoPa cohort. Neurology 81: 1226–1234. [Abstract]
  136. Patel S, Friede T, Froud R, Evans DW, Underwood M (2013) Systematic review of randomised controlled trials of clinical prediction rules for physical therapy in low back pain. Spine 38: 762–769. [Abstract].
  137. Schneider S, Schmidli H, Friede T (2013) Blinded sample size reestimation for recurrent event data with time trends. Statistics in Medicine 32: 5448–5457. [Abstract]
  138. Schneider S, Schmidli H, Friede T (2013) Blinded and unblinded internal pilot study designs for clinical trials with count data. Biometrical Journal 55: 617-633. [Abstract].
  139. Schneider S, Schmidli H, Friede T (2013) Robustness of methods for blinded sample size reestimation with overdispersed count data. Statistics in Medicine 32: 3623–3635. [Abstract]
  140. Steinvorth SM, Röver C, Schneider S, Nicholas R, Straube S, Friede T (2013) Explaining temporal trends in annualized relapse rates in placebo groups of randomized controlled trials in relapsing multiple sclerosis: Systematic review and meta-regression. Multiple Sclerosis Journal 19: 1580-1586. [Abstract]
  141. Taggart F, Friede T, Weich, Clarke A, Johnson MR, Stewart-Brown SL.(2013) Cross cultural evaluation of the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS). A mixed methods study. Health and Quality of Life Outcomes 11: 27. [Open Access]

  142. 2012
  143. Friede T, Miller F (2012) Blinded continuous monitoring of nuisance parameters in clinical trials. Journal of the Royal Statistical Society Series C 61: 601–618. [Abstract]
  144. Friede T, Parsons N, Stallard N (2012) A conditional error function approach for subgroup selection in adaptive clinical trials. Statistics in Medicine 31: 4309-4320. [Abstract]
  145. Gerlinger C, Edler L, Friede T, Kieser M, Nakas CT, Schumacher M, Seldrup J, Victor N (2012) Considerations on what constitutes a ”Qualified Statistician” in regulatory guidelines. Statistics in Medicine 31: 1303–1305. [Abstract]
  146. Goralczyk AD, Bari N, Abu-Ajaj W, Lorf T, Ramadori G, Friede T, Obed A (2012) Calcineurin inhibitor sparing with mycophenolate mofetil in liver transplantion: a systematic review of randomized controlled trials. American Journal of Transplantation 2012; 12: 2601–2607. [Abstract]
  147. Gross O , Licht C, Anders HJ, Hoppe B, Beck B, Tönshoff B, Höcker B, Wygoda S, Ehrich JHH, Pape L, Konrad M, Rascher W, Dötsch J, Müller-Wiefel DE, Hoyer P, and Study Group Members of the Gesellschaft für Pädiatrische Nephrologie (GPN), Knebelmann B, Pirson Y, Grunfeld JP, Niaudet P, Cochat P, Heidet L, Torra R, Friede T, Lange K, Müller GA, Weber M. (2012). Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney International 81: 494–501. [Abstract]
  148. Gross O, Friede T, Hilgers R, Görlitz A, Gavenis K, Ahmed R, Dürr U (2012) Safety and efficacy of the ACE-inhibitor ramipril in Alport syndrome: The double-blind, randomized, placebo-controlled, multicenter phase III EARLY PRO-TECT Alport trial in pediatric patients. ISRN Pediatrics Volume 2012, Article ID 436046, 6 pages, doi:10.5402/2012/436046. [Open Access PDF].
  149. Nicholas R, Friede T (2012) Considerations in the design of clinical trials for relapsing multiple sclerosis. Clinical Investigation 2: 1073-1083. [Abstract]
  150. Nicholas R, Straube S, Schmidli H, Pfeiffer S, Friede T (2012) Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: A systematic review and meta-analysis. Multiple Sclerosis Journal 18: 1290-1296. [Abstract]
  151. Parsons N, Friede T, Todd S, Valdés-Márquez E, Chataway J, Nicholas R, Stallard N (2012) An R package for implementing simulations for seamless phase II/III clinical trials using early outcomes for treatment selection. Computational Statistics and Data Analysis 56: 1150-1160. [Abstract]
  152. Pugliatti M, Eskic D, Mikolcić T, Pitschnau-Michel D, Myhr K-M, Sastre-Garriga J, Otero S, Wieczynska L, Torje C, Holloway E, Rienhoff O, Friede T, Buckow K, Ellenberger D, Hillert J, Glaser A, Flachenecker P, Fuge J, Schyns-Liharska T, Kasilingam E, Moretti A, Thalheim C for the EUReMS Consortium. (2012) Assess, compare and enhance the status of Persons with Multiple Sclerosis (MS) in Europe: a European Register for MS. Acta Neurologica Scandinavica 2012: 126 (Suppl. 195): 24–30. [Abstract]
  153. Seegers J, Vos MA, Willems R, Flevari P, Dorenkamp M, Sohns C, Vollmann D, Lüthje L, Kremastinos DT, Floré V, Meine M, Tuinenburg A, Connelly DT, Myles RC, Marshall GE, Simon D, Brockmöller J, Friede T, Hasenfuß G, Lehnart SE, Zabel M for the EUTrigTreat Clinical Study Investigators (2012) Rationale, objectives and design of the EUTrigTreat Clinical Study: A prospective observational study for arrhythmia risk stratification and assessment of interrelationships among repolarisation markers and genotype. EP-Europace 14: 416–422. [Abstract]

  154. 2011
  155. Chataway J, Nicholas R, Todd, S, Miller D, Parsons N, Valdés-Márquez E, Stallard N, Friede T (2011) A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Multiple Sclerosis 17: 81-88. [Abstract]
  156. Clarke A, Friede T, Putz R, Ashdown J, Martin S, Blake A, Adi Y, Parkinson J, Flynn P, Platt S, Stewart-Brown S. (2011) Warwick-Edinburgh Mental Well-being Scale (WEMWBS): Validated for teenage school students in England and Scotland. A mixed methods assessment. BMC Public Health 11: 487. [Open access]
  157. Friede T, Kieser M (2011) Reassessment of sample size in internal pilot study designs for non-inferiority trials evaluated with ANCOVA. Methods of Information in Medicine 50: 237-243. [Abstract]
  158. Friede T, Kieser M (2011) Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis. Pharmaceutical Statistics 10: 8-13. [Abstract]
  159. Friede T, Parsons N, Stallard N, Todd S, Valdés-Márquez E, Chataway J, Nicholas R (2011) Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: An application in multiple sclerosis. Statistics in Medicine 30: 1528-1540. [Abstract]
  160. Hua TD, Vormfelde SV, Abu Abed M, Schneider-Rudt H, Sobotta P, Friede T, Chenot JF (2011) Practice nursed-based, individual and video-assisted patient education in oral anticoagulation - Protocol of a cluster-randomized controlled trial. BMC Family Practice 12: 17. [Open access]
  161. Jung K, Friede T, Beißbarth T (2011) Reporting FDR analogous confidence intervals for the log fold change of differentially expressed genes. BMC Bioinformatics 12: 288. [Open access]
  162. Kieser M, Friede T (2011) Authors’ reply to Comments by G. Li on ‘Planning and analysis of three-arm non-inferiority trials with binary endpoints’. Statistics in Medicine 30: 300. [Abstract]
  163. Nicholas R, Giannetti P, Alanousi A, Friede T, Muraro PA (2011) Development of oral immunomodulatory agents in the management of multiple sclerosis. Drug Design, Development and Therapy 5: 255–274. [Open access]
  164. Nicholas R, Straube S, Schmidli H, Schneider S, Friede T (2011) Trends in annualized relapse rates in relapsing remitting multiple sclerosis and consequences for clinical trial design. Multiple Sclerosis Journal 17: 1211-1217. [Abstract]
  165. Patel S, Brown S, Friede T, Griffiths F, Lord J, Thistlethwaite J, Tysall C, Woolvine M, Underwood M (2011) Study protocol: Improving patient choice in treating low back pain (IMPACT - LBP): A randomised controlled trial of a decision support package for use in physical therapy. BMC Musculoskeletal Disorders 12: 52. [Open access]
  166. Thapar A, Lane T, Nicholas R, Friede T, Ellis M, Assenheim J, Franklin IJ, Davies AH (2011) Systematic review of sonographic CCSVI findings in multiple sclerosis. Phlebology 26: 319-25. [Abstract]

  167. 2010
  168. Friede T, Nicholas R, Stallard N, Todd S, Parsons N, Valdés-Márquez E, Chataway J (2010) Refinement of the Clinical Scenario Evaluation Framework for Assessment of Competing Development Strategies With an Application to Multiple Sclerosis . Drug Information Journal 44: 713-718. [Abstract]
  169. Friede T, Schmidli H (2010) Blinded sample size reestimation with count data: Methods and applications in multiple sclerosis. Statistics in Medicine 29: 1145-1156. [Abstract]
  170. Holt TA, Thorogood M, Griffiths F, Munday S, Friede T, Stables D (2010) Automated electronic reminders to facilitate primary cardiovascular disease prevention: randomised controlled trial.[ISRCTN64828380] British Journal of General Practice 60:251-256. [Abstract]
  171. Benda N, Brannath W, Bretz F, Burger HU, Friede T, Maurer W, Wang SJ (2010) Perspectives on the use of adaptive designs in clinical trials: Part II Panel Discussions. Journal of Biopharmaceutical Statistics 20: 1098 – 1112. [Abstract]
  172. Benda N, Branson M, Maurer W, Friede T (2010) Aspects of modernizing drug development using scenario planning and evaluation. Drug Information Journal 44: 299-315. [PDF]
  173. Friede T, Schmidli H (2010) Blinded sample size reestimation with negative binomial counts in superiority and non-inferiority trials. Methods of Information in Medicine 49:618-624. [Abstract]
  174. Friede T, Stammer H (2010) Blinded sample size recalculation in non-inferiority trials: A case study in dermatology . Drug Information Journal 44: 599-607. [PDF]
  175. Nicholas R, Young C, Friede T (2010) Bladder symptoms in Multiple Sclerosis: a review of pathophysiology and management. Expert Opinion on Drug Safety: 905-915. [Abstract]
  176. Stallard N, Friede T, Posch M, Koenig F, Brannath W (2010) Correction. STAT MED, 29: 614-5 [Abstract]

  177. 2009
  178. Benda N, Branson M, Maurer W, Friede T (2009) Clinical Scenario Evaluation: A framework for the evaluation of competing development strategies. Drug Development 4: 84-88.
  179. Friede T, Henderson R (2009) Exploring changes in treatment effects across design stages in adaptive trials. PHARM STAT 8: 62-72.
  180. Dale J, Caramlau I, Sturt J, Friede T, Walker R (2009) Telephone Peer-delivered Intervention for Diabetes Education and Support: The Telecare Exploratory RCT. Patient Education and Counseling 75: 91–98. [Abstract]
  181. Nicholas RS, Friede T, Hollis S, Young CA (2009) Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database of Systematic Reviews 1: CD004193. [Abstract]
  182. Miller F, Friede T, Kieser M (2009) Blinded assessment of treatment effects utilising information about the randomisation block length. Statistics in Medicine 28: 1690–1706. [Abstract]
  183. Stallard N, Posch M, Friede T, Koenig F, Brannath W (2009) Optimal choice of the number of treatments to be included in a clinical trial. Statistics in Medicine 28: 1321–1338. [Abstract]
  184. Friede T, Henderson R (2009) Exploring changes in treatment effects across design stages in adaptive trials. Pharmaceutical Statistics 8: 62-72. [Abstract]

  185. 2008
  186. Robertson W, Friede T, Blissett J, Rudolf MCJ, Wallis M, Stewart-Brown S (2008) Pilot of the Families for Health programme for the treatment of obesity. Archives of Disease in Childhood 93: 921–926.
  187. Friede T, Dunn J, Stallard N (2008) Clinical trials in oncology. In: Missailidis S (ed.): Anticancer therapeutics, Wiley-Blackwell, Chichester. Pages 365-375.
  188. Friede T, Stallard N (2008) A comparison of methods for adaptive treatment selection. Biometrical Journal 50: 767-781.
  189. Stallard N, Friede T (2008) Flexible group-sequential designs for clinical trials with treatment selection. Statistics in Medicine 27: 6209-6227.

  190. 2007
  191. Rog DJ, Nurmikko TJ, Friede T, Young CA (2007) Validation and reliability of the neuropathic pain scale (NPS) in multiple sclerosis. Clinical Journal of Pain 23: 473–481.
  192. Friede T, Mitchell C, Müller-Velten G (2007) Blinded sample size reestimation in non-inferiority studies with binary endpoints. Biometrical Journal 49: 903-916.
  193. Kieser M, Friede T (2007) Planning and analysis of three-arm non-inferiority trials with binary endpoints. Statistics in Medicine 26: 253-273.
  194. Friede T, Henderson R, Kao CF (2006) A note on testing for intervention effects on binary responses. Methods of Information in Medicine 45: 435-440.